Myocardial Infarction Clinical Trial
— BIO-GUARD-MIOfficial title:
BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Myocardial Infarction
Verified date | November 2022 |
Source | Biotronik SE & Co. KG |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The BIO|GUARD-MI study investigates whether continuous arrhythmia monitoring and the consequent treatment after detected arrhythmias in patients after myocardial infarction with preserved cardiac function, but other risk factors, decreases the risk of major adverse cardiac events.
Status | Completed |
Enrollment | 802 |
Est. completion date | November 3, 2021 |
Est. primary completion date | November 3, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - Patient has a history of MI according to guidelines - CHA2DS2-VASc-Score = 4 in men / = 5 in women - LVEF > 35 % as estimated within 6 months before enrollment but after conclusion of AMI treatment - Patient accepts activation of Home Monitoring® - Patient is able to understand the nature of the clinical study and has provided written informed consent Exclusion Criteria: - Patients with hemorrhagic diathesis - Permanent oral anticoagulation treatment for atrial fibrillation - Indication for chronic renal dialysis - Pacemaker or ICD implanted or indication for implantation - Parkinson's disease - Life expectancy < 1 year - Participation in another interventional clinical Investigation - Age < 18 years - Woman who are pregnant or breast feeding |
Country | Name | City | State |
---|---|---|---|
Australia | The Canberra Hospital | Canberra | |
Australia | Lyell McEwin Hospital (LMH) | Elizabeth Vale | South Australia |
Australia | East Metropolitan Health Service Trading AS Royal Perth HOSPITAL | Perth | Western Australia |
Austria | Kepler Universitätsklinikum | Linz | Oberösterreich |
Belgium | OLV Ziekenhuis Aalst | Aalst | |
Belgium | Ziekenhuis Oost Limburg Genk (ZOL Genk) | Genk | |
Czechia | Nemocnice Ceské Budejovice | Ceské Budejovice | |
Czechia | Fakultní nemocnice Olomouc | Olomouc | |
Czechia | Institute for Clinical and Experimental Medicine (IKEM) | Praha | |
Denmark | Aalborg Universitetshospitel | Aalborg | |
Denmark | Århus Universitetshospital | Århus N | |
Denmark | Rigshospitalet | Copenhagen | |
Denmark | Regionshospitalet Herning | Herning | |
Denmark | Odense University Hospital (OUH) | Odense | Syddanmark |
Denmark | Sjaellands Universitets Hospital, Roskilde | Roskilde | |
Denmark | Regionshospitalet Viborg | Viborg | |
France | CHRU de Tours - Hôpital Trousseau | Chambray-lès-Tours | |
France | Hôpital Gabriel Montpied, Clermont Ferrand | Clermont-Ferrand | |
Germany | Zentralklinik Bad Berka GmbH | Bad Berka | |
Germany | Herz- und Gefäß- Klinik GmbH Bad Neustadt | Bad Neustadt a.d. Saale | |
Germany | Charité Universitätsklinikum - Campus Benjamin Franklin | Berlin | |
Germany | Vivantes Humboldt-Klinikum | Berlin | |
Germany | Vivantes-Krankenhaus Spandau | Berlin | |
Germany | Städtisches Krankenhaus Bielefeld-Mitte | Bielefeld | |
Germany | Klinikum Coburg | Coburg | |
Germany | Klinikum Fürth | Fürth | |
Germany | SRH Wald-Klinikum Gera GmbH | Gera | |
Germany | Ernst-Moritz-Arndt-Universität Greifswald | Greifswald | |
Germany | Klinikum der Universität Jena | Jena | |
Germany | Herzzentrum Leipzig GmbH | Leipzig | |
Germany | Universitätsklinikum Schleswig-Holstein (UKSH) - Campus Lübeck | Lübeck | |
Germany | Johannes Wesling Klinikum Minden | Minden | |
Germany | Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH | Villingen-Schwenningen | |
Germany | Universitätsklinikum Würzburg | Würzburg | |
Hungary | National Hospital of Cardiology | Balatonfüred | |
Hungary | Gottsegen György | Budapest | |
Hungary | Hungarian Defence Forces Military Hospital | Budapest | |
Hungary | Semmelweis Medical University | Budapest | |
Hungary | The Debrecen University of Medicine | Debrecen | |
Hungary | The University of Pécs | Pécs | |
Latvia | Pauls Stradins Clinical University Hospital | Riga | |
Latvia | Riga East Clinical University Hospital | Riga | |
Netherlands | Onze Lieve Vrouwe Gasthuis Amsterdam (OLVG) | Amsterdam | |
Netherlands | Scheperziekenhuis, Treant Zorggroep | Emmen | |
Poland | Klinika i Katedra Chorób Wewn. i Kardiologii | Warszawa | |
Poland | National Institute of Cardiology | Warszawa | |
Slovakia | SÚSCCH | Banska Bystrica | |
Slovakia | East-Slovak Cardiology Institute (VUSCH) | Košice | |
Spain | Hospital del Mar | Barcelona | |
Spain | Hospital de la Princesa | Madrid | |
Spain | Hospital Universitario Ramón y Cajal | Madrid | |
United States | Abington Medical Specialists | Abington | Pennsylvania |
United States | Altru Health System | Grand Forks | North Dakota |
United States | Metro Knoxville HMA LLC | Knoxville | Tennessee |
United States | Carolina Heart Specialists | Lancaster | South Carolina |
United States | University of Rochester Medical Center | Rochester | New York |
United States | Carolina Cardiology Associates | Rock Hill | South Carolina |
United States | Gateway Cardiology | Saint Louis | Missouri |
United States | St. Louis Heart and Vascular | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Biotronik SE & Co. KG | IHF GmbH - Institut für Herzinfarktforschung, Qmed Consulting A/S |
United States, Australia, Austria, Belgium, Czechia, Denmark, France, Germany, Hungary, Latvia, Netherlands, Poland, Slovakia, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Mean Value of EQ-5D-5L | The EQ-5D-5L questionnaire was administered during the telephone contacts to estimate utility values at different time points for an economic evaluation.
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. The scale reaches from 0 (worst status) to 100 (best possible status). |
From Baseline measurement to 60 months. All data are collected for the period from randomization until official study end or drop-out, for all enrolled patients. | |
Primary | Kaplan-Meier Estimate of Percentage of Participants With Major Adverse Cardiac Event (MACE) | The primary endpoint is defined as death for cardiovascular reasons or unplanned hospitalization for cardiovascular reasons as per study protocol.
The time period with regards to the Time-to-Event Outcome Measures starts with the randomization of the patient. All patients will be assessed for Time-to-Event Outcome Measures until formal study termination is announced or until the individual patient meets a drop out criterion in accordance with the study protocol. The study period is estimated 6 years. |
2 years | |
Secondary | Kaplan-Meier Estimate of Percentage of Participants With Outcome of Death Due to Any Cause | The occurrence of death due to any cause will be recorded and analyzed. | 2 years | |
Secondary | Kaplan-Meier Estimate of Percentage of Participants With Outcome of Death Due to Any Cause or Heart Transplantation | Assessment of the time from randomization to death for any reason or heart transplantation during the clinical investigation. | 2 years | |
Secondary | Kaplan-Meier Estimate of Percentage of Participants With Outcome of Cardiovascular Death or Heart Transplantation | Assessment of the time from randomization to cardiovascular death or heart transplantation during the clinical investigation. A specified endpoint definition will be given by the members of the EAEC and documented in the charter agreement. | 2 years | |
Secondary | Kaplan-Meier Estimate of Percentage of Participants With Worsening of Heart Failure Requiring Hospitalization or Urgent Visit | Assessment of the time from randomization to first hospitalization or urgent visit for worsening of the patient status due to heart failure, or death due to heart failure. A specified endpoint definition will be given by the members of the EAEC and documented in the charter agreement. | 2 years | |
Secondary | Kaplan-Meier Estimate of Percentage of Participants With an Arrhythmia Resulting in Hospitalization | Assessment of the time from randomization to the first hospitalization resulting from an arrhythmia or death resulting from arrhythmia. A specified endpoint definition will be given by the members of the EAEC and documented in the charter agreement. | 2 years | |
Secondary | Kaplan-Meier Estimate of Percentage of Participants With Acute Coronary Syndrome Resulting in Hospitalization | Assessment of the time from randomization to the first hospitalization resulting from acute coronary syndrome or death resulting from acute coronary syndrome. A specified endpoint definition will be given by the members of the EAEC and documented in the charter agreement. | 2 years | |
Secondary | Kaplan-Meier Estimate of Percentage of Participants With Stroke Resulting in Hospitalization | Assessment of the time from randomization to the first hospitalization resulting from stroke or death resulting from stroke. A specified endpoint definition will be given by the members of the EAEC and documented in the charter agreement. | 2 years | |
Secondary | Kaplan-Meier Estimate of Percentage of Participants With Major Bleeding Resulting in Hospitalization | Assessment of the time from randomization to the first hospitalization resulting from major bleeding or death resulting from major bleeding. A specified endpoint definition will be given by the members of the EAEC and documented in the charter agreement. | 2 years | |
Secondary | Kaplan-Meier Estimate of Percentage of Participants With Systemic Embolism Resulting in Hospitalization | Assessment of the time from randomization to the first hospitalization resulting from systemic embolism or death resulting from systemic embolism. A specified endpoint definition will be given by the members of the EAEC and documented in the charter agreement. | 2 years | |
Secondary | Kaplan-Meier Estimate of Percentage of Participants With an Arrhythmia | Assessment of the time from randomization to first arrhythmia. | 2 years | |
Secondary | Type of Initiated Therapies | Post-hoc categorical summary of most frequent therapies initiated after detection of arrhythmias. | All data are collected for the period from randomization until official study end or drop-out, for all enrolled patients, up to 6 years. | |
Secondary | Kaplan-Meier Estimate of Percentage of Participants Receiving Therapy After Arrhythmia Diagnosis | Assessment of the time from randomization to first therapy. In this context therapy is the attempted remediation of the patient's regular heartbeat. | 2 years | |
Secondary | Change in World Health Organization Five Well-being Index (WHO-5) From 6 Months to 24 Months. | A further secondary endpoint is the assessment of the patient's well-being. The patient's well-being will be recorded during the regular telephone contacts using the WHO-5 Well-being Index. The scale reaches from 0 (worst status) to 100 (best possible status). | We report the intraindividual change from 6-months to 24-months. All data are collected for the period from randomization until official study end or drop-out, for all enrolled patients. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
Completed |
NCT04507529 -
Peer-mentor Support for Older Vulnerable Myocardial Infarction Patients
|
N/A | |
Recruiting |
NCT06066970 -
Cardiac Biomarkers for the Quantification of Myocardial Damage After Cardiac Surgery
|
||
Recruiting |
NCT03620266 -
Effects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI
|
N/A | |
Completed |
NCT04097912 -
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
|
||
Completed |
NCT04153006 -
Comparison of Fingerstick Versus Venous Sample for Troponin I.
|
||
Completed |
NCT03668587 -
Feasibility and Security of a Rapid Rule-out and rule-in Troponin Protocol in the Management of NSTEMI in an Emergency Departement
|
||
Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
Completed |
NCT03076801 -
Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?
|
N/A | |
Recruiting |
NCT05371470 -
Voice Analysis Technology to Detect and Manage Depression and Anxiety in Cardiac Rehabilitation
|
N/A | |
Recruiting |
NCT04562272 -
Attenuation of Post-infarct LV Remodeling by Mechanical Unloading Using Impella-CP
|
N/A | |
Completed |
NCT04584645 -
A Digital Flu Intervention for People With Cardiovascular Conditions
|
N/A | |
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Not yet recruiting |
NCT06007950 -
Time-restricted Eating Study (TRES): Impacts on Anthropometric, Cardiometabolic and Cardiovascular Health
|
N/A | |
Withdrawn |
NCT05327855 -
Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI)
|
Phase 2 | |
Recruiting |
NCT02876952 -
High Intensity Aerobic Interval Training With Mediterranean Diet Recommendations in Post-Myocardial Infarct Patients
|
N/A | |
Completed |
NCT02917213 -
Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
|
||
Completed |
NCT02711631 -
Feasibility and Effectiveness of Remote Virtual Reality-Based Cardiac Rehabilitation
|
N/A | |
Completed |
NCT02552407 -
Thrombectomy in ST Elevation Myocardial Infarction, an Individual Patient Meta-analysis
|
N/A | |
Completed |
NCT02382731 -
Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction
|
N/A |